రెక్టల్ క్యాన్సర్
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
ఎక్కడికి వెళ్లాలి
ఈ trial కోసం ఇండియాలో 8 హాస్పిటల్స్ పేషెంట్లను తీసుకుంటున్నాయి.
రిజిస్ట్రీ సమ్మరీ (టెక్నికల్)
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectabl…
Sponsor: జాన్సన్ రీసెర్చ్ & డెవలప్మెంట్, LLC
NCT06750094 on ClinicalTrials.gov
Last updated on the registry 25 Sep 2026 · read by us 20 Oct 2026